top of page

Psychedelic-Assisted Therapy: Healthcare Policies and Ethical Practices

Learn about the ethics and healthcare policies involved in psychedelic-assisted therapy. Jordanna Davis and Jacqueline Lampert join to discuss the implications.

Episode Summary

Welcome to the first episode in our three-part series where we explore the world of psychedelic therapy. In this episode, health policy experts Jordanna Davis and Jacqueline Lampert join to discuss the experiences of psychedelic-assisted therapy and its profound social implications. This series aims to uncover the complexities and potential of psychedelic mental health treatment options.

Key Takeaways
  • Controversial medical debate on whether psychedelic therapy practitioners should have personal psychedelic experiences

  • Concerns around cultural appropriation in psychedelic therapies and the need for respectful acknowledgment of indigenous practices

  • The complexity of patient-clinician dynamics if a patient prefers a provider who has personal experience of their condition

  • Significance of professional practice guidelines that ensure ethical and culturally sensitive approaches in guided psychedelic therapy

  • The future of psychedelics in therapy and its potential to revolutionize mental health care

Enjoy this insightful first episode as we unravel psychedelics and mental health with Jordanna Davis and Jacqueline Lampert. Tune in for the next two episodes of this exciting series dedicated to exploring psychedelic therapy research.

Related to this episode:

If you want to support this women’s health podcast, leave a review for Fempower Health on iTunes or Spotify.

Spread the awareness and share this episode with someone you know!

Support and connect with our women’s health community:

Guest Bios

Jordanna Davis is the President of Rockingstone Group, a New York-based health policy consulting firm serving a diverse clientele including hospitals, health plans, and tech companies. Prior to founding Rockingstone in 2016, she was integral to the operations at Sachs Policy Group, advising New York's major health systems. Jordanna's extensive experience in Washington, D.C., includes roles as a Health Care Fellow for Senator Russ Feingold and a Legislative Assistant for Senator Sheldon Whitehouse, contributing significantly to the Affordable Care Act. She also brings experience from the Georgetown Health Policy Institute and the Greater New York Hospital Association. Jordanna is a board member of the New York eHealth Collaborative and holds a BA from Yale University and an MPP from Georgetown University. She resides in New York with her family.

Jacqueline Lampert is a Principal at Rockingstone Group, specializing in health consulting that combines policy expertise with experience in various healthcare sectors. She played a pivotal role as a health policy advisor for the U.S. Senate Democratic Policy Committee, contributing to the Affordable Care Act under Senate Majority Leader Harry Reid. Her career also includes legislative work for Senator Tim Johnson and roles at UPMC and New York Life Insurance Company. Jacqueline holds a Master of Public Policy from Georgetown University and a Bachelor's in Communication from Northwestern University. She resides in Ohio with her family.


Georgie Kovacs:

Join us as we delve deeper with Jordana and Jacqueline into how this evolving landscape is reshaping the future of mental health care.

Georgie Kovacs:

Thank you so much for joining the Fempower Health podcast. It's so interesting how this psychedelic series has come about. I've been thinking about it for a really long time and I wasn't really sure how to approach it. I had read Michael Pollan's history and I knew about his book, but I was like, I don't know if that's the know expert to have on the podcast. And I was talking to a dear friend of mine who is also a healthcare consultant, and she told me that I should speak with Jordana. So, Jordana, you and I had a call, and I thought this was going to be a very simple conversation. We'd do an episode and then we'd be done talking psychedelics. And you educated me on all these things that I didn't even realize we needed to discuss.

Georgie Kovacs:

And so I really appreciate you educating me on that. And we're going to talk about that today because it's inspired a three part series, and I'm actually doing series now on lots of health topics because I do think a lot of them warrant more than one episode. And so thank you for helping get the ball rolling on that. So, without further ado, before we dive into the topic, why don't we do some introductions and we can take it from there? So, Jordana, since I brought up your name, why don't you go ahead and start?

Jordanna Davis:

Thanks, Georgie. We're so excited to be here. I'm Jordana Davis. I'm the president of the Rockingstone Group. We're a health policy consulting firm in New York. My background is in the federal government. So I worked for two senators during the drafting and passage of the Affordable Care act. And we've been working on the policy side of psychedelic medicine for about three years.

Jacqueline Lampert:

And Jacqueline, I'll just echo Jordana's. Thanks, Georgie. It's so exciting to be with you today to talk about this exciting work. My name is Jacqueline Lampert. I'm a principal with the Rockingstone Group. Jordana is based in New York. I'm based in Ohio, and I also have a background in the federal government. I worked for also two different senators, including Senate leadership, during drafting and passage of the Affordable Care act.

Jacqueline Lampert:

And then once I left the Senate, I worked a payer in a health insurer and also a provider, and have been consulting for a number of years. We consult with a range of different healthcare organizations, providers, payers, advocacy organizations, health tec